ReviewFrontiers in cell and developmental biology2026
Ferroptosis in liver diseases: molecular mechanisms, biomarker potential, and clinical translation.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is a type of intracellular, iron-dependent cell death that differs from apoptosis, necrosis, and autophagy. Ferroptosis is characterized by excessive lipid peroxidation. Iron-dependent, non-apoptotic cell death is linked to several liver diseases. Although numerous ferroptosis-associated genes and pathways have been linked to liver disorders, the exact mechanisms by which ferroptosis contributes to disease initiation and progression remain incompletely understood. In this review, we discuss the initiation and role of ferroptosis in the pathophysiology of liver diseases, including acute liver injury, liver fibrosis, hepatocellular carcinoma, viral hepatitis, autoimmune hepatitis, alcohol-associated liver disease, and NAFLD/MASLD. We first describe the regulatory function of ferroptosis before highlighting its relevance and underlying processes in several distinct liver disorders. In addition, we briefly discuss the potential clinical relevance of ferroptosis-related molecules and pathways as candidate biomarkers and therapeutic targets in liver diseases, with emphasis on their possible value in biomarker discovery, patient stratification, disease evaluation, and clinical translation. We also emphasize the context-dependent role of ferroptosis, in which its induction may be therapeutically beneficial in hepatocellular carcinoma or activated hepatic stellate cells, whereas excessive hepatocyte ferroptosis may aggravate non-malignant liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.